Kenai Therapeutics

Kenai Therapeutics advances allogeneic cell therapies for neurological disorders, including Parkinson’s, supported by $82M funding to progress clinical trials and innovation.

Kenai Therapeutics develops neuron replacement therapies for neurological conditions under new CTO Dr. Derek Hei.

Kenai Therapeutics advances Parkinson’s research through a new Patient Advisory Board and cell therapy development for neurological conditions.

Kenai Therapeutics describes its mission, leadership, and scientific work in healthcare solutions.

Kenai Therapeutics advances stem cell-based treatments for neurological disorders like Parkinson's, focusing on neuron replacement therapies with promising preclinical results.

Kenai Therapeutics adds Mark J. Gergen to its Board of Directors. Gergen brings over 30 years of experience in biotech operations and transactions. The company focuses on developing next-generation treatments for neurological conditions.

Aug 2026Kenai TherapeuticsNews article

Kenai Therapeutics names Blake Arnold as Chief Business Officer. Arnold will oversee business development, financing, strategic partnerships, and corporate initiatives to advance the company’s clinical-stage pipeline for neurological treatments. The appointment supports Kenai’s growth in developing next-generation therapies for neurological conditions.

Feb 2026Kenai TherapeuticsNews article

Kenai Therapeutics doses the first patient in its Phase 1 **REPLACE™** trial of **RNDP-001**, a neuron replacement cell therapy targeting idiopathic Parkinson’s disease. The U.S. FDA has granted **Fast Track designation** to accelerate the therapy’s development and review process. The trial evaluates safety and potential efficacy of the investigational treatment in patients with Parkinson’s.

Dec 2025Kenai TherapeuticsNews article

Kenai Therapeutics opens a research and laboratory facility at Lilly Gateway Labs in San Diego to advance its off-the-shelf neuron replacement therapies using induced pluripotent stem cell (iPSC) technology. The company joins Gateway Labs, a partnership between Lilly and Alexandria Real Estate Equities, to accelerate development for neurological conditions. Kenai’s platform focuses on discovering and developing stem cell-based treatments for neurological disorders.

Feb 2025Kenai TherapeuticsNews article